An increased SCARA3 concentration reduced myeloma cell destruction operated by BTZ and dexamethasone and BTZ, while SCARA3 knockdown augmented the sensitivity of MM cells to these drugs. The gene discussed is SCARA3; the disease is plasma cell myeloma.